Dr. Mark Socinski from University of Pittsburgh summarizes and
critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva
(erlotinib) in EGFR wild type advanced NSCLC.
About the Podcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.